İbrahim Öner Doğan
Research Subjects
Research Interests
İbrahim Öner Doğan has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Taner Tan
Koç University, School of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul, Türkiye
3 shared publications - Olga Meltem Akay
Koç University, School of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul, Türkiye
2 shared publications - Gülçin Yeğen
İstanbul University, İstanbul Faculty of Medicine, Department of Pathology, İstanbul, Türkiye
1 shared publication Merve Kaysin
Koç University Hospital, Genetic Disorders Assessment Center, İstanbul, Türkiye
1 shared publicationMustafa Cem Bülbül
Koç University Faculty of Medicine, Department of Internal Medicine, İstanbul, Türkiye
1 shared publication- Neslihan Berker
Department of Pathology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
1 shared publication
Latest Publications
- Open Access
- 17 February 2025
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 42 (3) , 223-224
Decoding Cytoplasmic Vacuolization: Unravelling the Diagnostic Challenges of Vexas Syndrome
- 17 February 2025
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 42 (3) , 223-224
Open AccessDecoding Cytoplasmic Vacuolization: Unravelling the Diagnostic Challenges of Vexas Syndrome
- Open Access
- 14 November 2024
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 2 (4) , 93-94
Can bispecific antibody therapies for multiple myeloma be a risk factor for the development of secondary haemotopoietic malignancy? A case report
With the introduction of many new treatments in multiple myeloma and the effective use of autologous stem cell transplantation, significant prolongation of overall survival has been achieved. Despite this ,there is still no cure for this disease. Relapses/refractory conditions seen after multiple treatments have brought the use of new agents to the agenda. Elranatamab is a humanized bispecific antibody used in relapsed or refractory multiple myeloma which targets B-cell maturation antigen on myeloma cells and CD3 on T cells . With this mechanism, elranatamab could activate T cells to induce cytotoxic T-cell response against myeloma cells. (1) Although we have an idea and experience about the short-term adverse effect profile and management, our ideas about the long-term adverse effect and safety profile are not yet clear due to the fact that it is a very new agent. We described an unexpected hematologic event during the use of elranatamab in the following case.
- 14 November 2024
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 2 (4) , 93-94
Open AccessCan bispecific antibody therapies for multiple myeloma be a risk factor for the development of secondary haemotopoietic malignancy? A case report
With the introduction of many new treatments in multiple myeloma and the effective use of autologous stem cell transplantation, significant prolongation of overall survival has been achieved. Despite this ,there is still no cure for this disease. Relapses/refractory conditions seen after multiple treatments have brought the use of new agents to the agenda. Elranatamab is a humanized bispecific antibody used in relapsed or refractory multiple myeloma which targets B-cell maturation antigen on myeloma cells and CD3 on T cells . With this mechanism, elranatamab could activate T cells to induce cytotoxic T-cell response against myeloma cells. (1) Although we have an idea and experience about the short-term adverse effect profile and management, our ideas about the long-term adverse effect and safety profile are not yet clear due to the fact that it is a very new agent. We described an unexpected hematologic event during the use of elranatamab in the following case.
- Open Access
- 1 September 2023
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 40 (3) , 162-173
Value of GCET1, HGAL (GCET2), and LMO2 in the Determination of Germinal Center Phenotype in Diffuse Large B-cell Lymphoma
Objective: Diffuse large B-cell lymphoma (DLBCL) is a biologically heterogeneous disease that is classified into germinal center B-cell (GCB) and non-GCB subtypes, which are prognostically different. The Hans algorithm is the most widely used tool based on CD10, BCL6, and MUM1 expression, but some cases with the non-GCB phenotype are still known to be misclassified. In this study, we investigate the extent to which GCET1, HGAL, and LMO2 protein expressions reflect GCB phenotype together with their roles in determining the GCB phenotype of DLBCL and their contributions to the performance of the Hans algorithm.Materials and Methods: Sixty-five cases of DLBCL-not otherwise specified, 40 cases of follicular lymphoma (FL), and 19 non-GC-derived lymphoma cases were included in this study. The DLBCL cases were grouped as CD10+ (Group A) or only MUM1+ (Group B), and the remaining cases constituted the intermediate group (Group C). GCET1, HGAL, and LMO2 expressions were evaluated.Results: In the FL group, GCET1, HGAL, and LMO2 were positive in 85%, 77.5%, and 100% of the cases, respectively. Among the non-GC derived lymphoma cases, all three markers were negative in cases of small lymphocytic lymphoma, plasmablastic lymphoma, peripheral T-cell lymphoma, and anaplastic large cell lymphoma. GCET1 and HGAL were negative in cases of marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL). Two of the 3 MZL and 2 of the 4 MCL cases were positive for LMO2. In the DLBCL group, the number of cases with GCET1, HGAL, and LMO2 positivity was 18 (90%), 17 (85%), and 20 (100%), respectively, in Group A and 0 (0%), 2 (13.3%), and 2 (13.3%), respectively, in Group B. Considering these rates, when the cases in the intermediate group were evaluated, it was concluded that 13 cases typed as non-GCB according to the Hans algorithm may have the GCB phenotype.Conclusion: GCET1, HGAL, and LMO2 are highly sensitive markers for determining the germinal center cell phenotype and can increase the accuracy of the subclassification of DLBCL cases, especially for cases that are negative for CD10.
- 1 September 2023
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 40 (3) , 162-173
Open AccessValue of GCET1, HGAL (GCET2), and LMO2 in the Determination of Germinal Center Phenotype in Diffuse Large B-cell Lymphoma
Objective: Diffuse large B-cell lymphoma (DLBCL) is a biologically heterogeneous disease that is classified into germinal center B-cell (GCB) and non-GCB subtypes, which are prognostically different. The Hans algorithm is the most widely used tool based on CD10, BCL6, and MUM1 expression, but some cases with the non-GCB phenotype are still known to be misclassified. In this study, we investigate the extent to which GCET1, HGAL, and LMO2 protein expressions reflect GCB phenotype together with their roles in determining the GCB phenotype of DLBCL and their contributions to the performance of the Hans algorithm.Materials and Methods: Sixty-five cases of DLBCL-not otherwise specified, 40 cases of follicular lymphoma (FL), and 19 non-GC-derived lymphoma cases were included in this study. The DLBCL cases were grouped as CD10+ (Group A) or only MUM1+ (Group B), and the remaining cases constituted the intermediate group (Group C). GCET1, HGAL, and LMO2 expressions were evaluated.Results: In the FL group, GCET1, HGAL, and LMO2 were positive in 85%, 77.5%, and 100% of the cases, respectively. Among the non-GC derived lymphoma cases, all three markers were negative in cases of small lymphocytic lymphoma, plasmablastic lymphoma, peripheral T-cell lymphoma, and anaplastic large cell lymphoma. GCET1 and HGAL were negative in cases of marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL). Two of the 3 MZL and 2 of the 4 MCL cases were positive for LMO2. In the DLBCL group, the number of cases with GCET1, HGAL, and LMO2 positivity was 18 (90%), 17 (85%), and 20 (100%), respectively, in Group A and 0 (0%), 2 (13.3%), and 2 (13.3%), respectively, in Group B. Considering these rates, when the cases in the intermediate group were evaluated, it was concluded that 13 cases typed as non-GCB according to the Hans algorithm may have the GCB phenotype.Conclusion: GCET1, HGAL, and LMO2 are highly sensitive markers for determining the germinal center cell phenotype and can increase the accuracy of the subclassification of DLBCL cases, especially for cases that are negative for CD10.
- Open Access
- 30 May 2023
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 40 (2) , 128-129
Charcot-Leiden Crystals in Acute Myeloid Leukemia with Bone Marrow Necrosis
- 30 May 2023
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 40 (2) , 128-129
Open AccessCharcot-Leiden Crystals in Acute Myeloid Leukemia with Bone Marrow Necrosis